Aerie Pharmaceuticals, Inc. (AERI): Price and Financial Metrics


Aerie Pharmaceuticals, Inc. (AERI): $15.78

-0.08 (-0.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AERI POWR Grades


  • Growth is the dimension where AERI ranks best; there it ranks ahead of 80.91% of US stocks.
  • AERI's strongest trending metric is Stability; it's been moving up over the last 31 weeks.
  • AERI ranks lowest in Momentum; there it ranks in the 5th percentile.

AERI Stock Summary

  • Aerie Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 1.53% of US listed stocks.
  • AERI's price/sales ratio is 8.76; that's higher than the P/S ratio of 79.45% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 9.28 for Aerie Pharmaceuticals Inc; that's greater than it is for 89.19% of US stocks.
  • Stocks that are quantitatively similar to AERI, based on their financial statements, market capitalization, and price volatility, are RCM, NETE, PCSB, AFIB, and PFIS.
  • AERI's SEC filings can be seen here. And to visit Aerie Pharmaceuticals Inc's official web site, go to www.aeriepharma.com.

AERI Valuation Summary

  • AERI's price/earnings ratio is -4.1; this is 112.06% lower than that of the median Healthcare stock.
  • Over the past 94 months, AERI's EV/EBIT ratio has gone up 7.5.
  • Over the past 94 months, AERI's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for AERI.

Stock Date P/S P/B P/E EV/EBIT
AERI 2020-02-06 16.4 4.7 -5.0 -4.8
AERI 2019-06-12 42.3 7.7 -6.2 -5.6
AERI 2018-08-06 NA 10.9 -16.1 -15.1
AERI 2018-04-03 NA 15.3 -14.3 -13.6
AERI 2015-03-23 NA 26.9 -15.7 -16.5
AERI 2013-12-10 NA -4.4 -20.8 -21.3

AERI Growth Metrics

  • Its 4 year price growth rate is now at -8.95%.
  • Its 5 year cash and equivalents growth rate is now at 25.46%.
  • Its 5 year price growth rate is now at -44.7%.
Over the past 30 months, AERI's revenue has gone up $76,042,000.

The table below shows AERI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 85.767 -52.922 -175.936
2020-12-31 83.138 -64.69 -183.101
2020-09-30 83.112 -114.176 -192.028
2020-06-30 81.575 -130.014 -201.782
2020-03-31 79.377 -143.613 -200.759
2019-12-31 69.888 -150.43 -199.581

AERI Price Target

For more insight on analysts targets of AERI, see our AERI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.25 Average Broker Recommendation 1.46 (Moderate Buy)

AERI Stock Price Chart Interactive Chart >

Price chart for AERI

AERI Price/Volume Stats

Current price $15.78 52-week high $21.30
Prev. close $15.86 52-week low $9.01
Day low $15.38 Volume 277,200
Day high $15.97 Avg. volume 581,585
50-day MA $16.18 Dividend yield N/A
200-day MA $15.65 Market Cap 739.97M

Aerie Pharmaceuticals, Inc. (AERI) Company Bio


Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company was founded in 2005 and is based in Irvine, California.


AERI Latest News Stream


Event/Time News Detail
Loading, please wait...

AERI Latest Social Stream


Loading social stream, please wait...

View Full AERI Social Stream

Latest AERI News From Around the Web

Below are the latest news stories about Aerie Pharmaceuticals Inc that investors may wish to consider to help them evaluate AERI as an investment opportunity.

Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021

DURHAM, N.C., July 28, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its first quarter 2021 financial results will be released after the market closes on Wednesday, August 4, 2021. Following the release, the Company will host a live conference call

Yahoo | July 28, 2021

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that David A. Hollander, M.D., M.B.A., Chief Research & Development Officer presented an overview on Aeries globalization outlook at the Ophthalmology Innovation Summit Europea

Business Wire | July 20, 2021

Aerie Pharmaceuticals Inc (AERI): Are Hedge Funds Right About This Stock?

No summary available.

Insider Monkey | July 19, 2021

Ophthalmic Drugs Market Impressive Gains including key players- Aerie Pharmaceuticals Inc., Abbive (Allergan), Bausch Health, Bayer AG, F. Hoffmann-La Roche Ltd

Latest released, the research study on Global Ophthalmic Drugs Market Report Forecast 2021 - 2025, offers a detailed overview of the factors influencing the global business scope. Ophthalmic Drugs Market research report shows the latest market insights, current situation analysis

OpenPR | July 17, 2021

Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Leon J. Atencia, Director of Regulatory Affairs, reporting to Emma Beausang, Aeries Vice President of Regulatory Affairs. Mr. Atencia will be responsible for clini

Business Wire | July 15, 2021

Read More 'AERI' Stories Here

AERI Price Returns

1-mo -1.44%
3-mo -8.73%
6-mo -2.71%
1-year 36.51%
3-year -76.78%
5-year -9.00%
YTD 16.80%
2020 -44.10%
2019 -33.05%
2018 -39.58%
2017 57.86%
2016 55.44%

Continue Researching AERI

Want to see what other sources are saying about Aerie Pharmaceuticals Inc's financials and stock price? Try the links below:

Aerie Pharmaceuticals Inc (AERI) Stock Price | Nasdaq
Aerie Pharmaceuticals Inc (AERI) Stock Quote, History and News - Yahoo Finance
Aerie Pharmaceuticals Inc (AERI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8521 seconds.